Front Pharmacol 13:1034515
Our retrospective cohort study showed results consistent with Uedas work, indicating that GLP-1RAs were not associated with a significant risk of intestinal obstruction compared to SGLT2 inhibitors
This difference highlights how the drugs action on the digestive system can lead to discomfort
To illustrate how storage requirements vary between licensed peptide medicines, and why extrapolation is unreliable: Semaglutide (Ozempic, Wegovy) according to the respective Summaries of Product Characteristics (SmPCs) on the Electronic Medicines Compendium (EMC), these products may be stored below 30C for a defined period after first use, but conditions differ between formulations Liraglutide (Saxenda) the SmPC specifies a different room-temperature allowance and duration Tirzepatide (Mounjaro) a dual GIP/GLP-1 agonist with its own distinct storage instructions [11] [12] These examples demonstrate that even closely related agents have product-specific requirements that cannot be applied to retatrutide
IUBMB Life 66(3):212219 Ichihara K, Hosogaya S, Okutani R, Yoshimoto S, Itoh K, Kameko M, Kayamori Y, Takagi Y, Nakano Y, Haga R, Motonaga H (2006) Protocols of determining limits of detection and limits of quantitation for quantitative analytical methods
For example, a randomized trial in overweight and obese women found that those taking bupropion had different average weight changes than those on placebo
